期刊名称：DRUG DESIGN DEVELOPMENT AND THERAPY ISSN： 1177-8881 出版频率： Continuous publication 出版社： DOVE MEDICAL PRESS LTD, PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752   出版社网址： http://www.dovepress.com/ 期刊网址： http://www.dovepress.com/drug-design-development-and-therapy-journal 影响因子： 4.162 主题范畴： CHEMISTRY, MEDICINAL;    PHARMACOLOGY & PHARMACY 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Drug Design, Development and Therapy  Editor-in-Chief: Daniel S Pilch, PhD ISSN: 1177-8881  An international, peer-reviewed, open access journal that spans the spectrum of drug design and development through to clinical applications. The journal is characterized by the rapid reporting of application notes, reviews, original research and clinical studies in all therapeutic areas. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines will be a feature of the journal.  This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE). Journal Impact Factor: 3.486 Indexed online in: PubMed (Drug Des Devel Ther) MedLine on MEDLARs Science Citation Index Expanded (also known as SciSearch®) Current Contents®/Clinical Medicine Journal Citation Reports Biological Abstracts BIOSIS Previews Embase Scopus Cases Database Google Scholar OAIster: The Open Access Initiative ResearchGATE scientific network   Article Processing Statistics: 16 Days From submission of manuscript to first editorial decision (including peer-review) 36 Days From editorial acceptance to publication Aims and Scope  Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design and development through to clinical applications. The journal is characterized by the rapid reporting of application notes, reviews, original research and clinical studies in all therapeutic areas. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines will be a feature of the journal.   Instructions to Authors   Call for Papers Drug, Design, Development and Therapy is indexed online: PubMed (Drug Des Devel Ther) MedLine on MEDLARs Science Citation Index Expanded (also known as SciSearch®) Current Contents®/Clinical Medicine Journal Citation Reports Biological Abstracts BIOSIS Previews Embase Scopus Cases Database Google Scholar OAIster: The Open Access Initiative ResearchGATE scientific network Journal Impact Factor: 3.486 What is the advantage to you of publishing in Drug Design, Development and Therapy? It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website. Although Drug Design, Development and Therapy receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish. The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Drug Design, Development and Therapy has one of the fastest turnaround times of any medical journal in the world. Generally peer review is complete within 2-3 weeks and the editor’s decision within 2-7 days of this. It is therefore very rare to have to wait more than 4 weeks for a final decision.  Many authors have found that our peer reviewer’s comments substantially add to their final papers. To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution a publication processing fee. PubMed Central Drug Design, Development and Therapy is indexed on PubMed and Medline (title abbreviation: Drug Des Devel Ther). All published papers in this journal are submitted to PubMed for indexing straight away.  Become a Favored Author and receive real benefits If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so.  Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee. Click here to go through to the Favored Author signup page, you'll just need to supply the working title of your next paper and when you intend to submit by. Yours sincerely Daniel S. Pilch Editor-in-Chief Drug Design, Development and Therapy Email: editor-in-chief@dovepress.com   Editorial Board Dr Pilch Editor-in-Chief: Dr Daniel Pilch Dr Pilch is an Associate Professor of Pharmacology at the Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey.  He earned his Baccalaureate degree in Zoology at the University of California, Berkeley, graduating in 1981.  After spending several years working in the industrial sector, he joined the laboratory of Richard H. Shafer at the University of California, San Francisco, where he conducted doctoral work centered on higher order nucleic acid structure and chemistry.  He earned his Ph.D. in Biophysics in 1991, whereupon he was awarded a Chateaubriand Fellowship by the French Ministry of Foreign Affairs to conduct postdoctoral work with Claude Hélène in the Biophysics Laboratory of the National Museum of Natural History in Paris.  After two years in Paris, where he focused on the development of small molecules that target nucleic acids in a structure-specific manner, he moved back across the Atlantic to continue his postdoctoral work in small molecule-nucleic acid recognition with Kenneth J. Breslauer at Rutgers University.  In 1998, he was appointed to the faculty at the University of Medicine and Dentistry of New Jersey. His current research interests are centered on the design and development of novel antimicrobial and anticancer agents.  In this connection, he employs a multidisciplinary approach toward understanding the molecular determinants of drug action and specificity, overcoming mechanisms of drug resistance, and enhancing drug bioavailability.  He has served on Study Sections for both the American Cancer Society and the National Institutes of Health.  He was the recipient of a New Investigator Award from the Cancer Institute of New Jersey and has served as a scientific consultant to the pharmaceutical industry in connection with the application of calorimetric techniques for drug screening and identification. Apart from his scientific endeavors, he is a devoted family man and avid baseball fan, with interests that include music and archaeology. Professor LaVoie Associate Editor: Professor Edmond LaVoie Professor LaVoie is Professor of Medicinal Chemistry at the Ernest Mario School of Pharmacy within Rutgers, The State University of New Jersey.  He earned his Baccalaureate degree in Chemistry at Fordham University in New York in 1971 and his PhD degree in Medicinal Chemistry at the State University of New York at Buffalo in 1975.  He also served as a Postdoctoral Fellow under the direction of S Morris Kupchan in the Department of Chemistry at the University of Virginia.  He worked at the American Health Foundation within the Naylor Dana Institute in Valhalla, New York for 12 years as Head of the Section of Metabolic Epidemiology and Associate Division Chief of Environmental Carcinogenesis.  In 1988, Dr LaVoie  was appointed Professor of Medicinal Chemistry within Rutgers University.  He is presently Chair of the Department of Medicinal Chemistry at the Ernest Mario School of Pharmacy.  He is also a co-founder of two pharmaceutical companies, TAXIS Pharmaceutical, Inc. and Prodaptics Pharmaceuticals, Inc.  He has served on Study Sections and Scientific Review for the National Institutes of Health, the National Institutes of Environmental Health Sciences, the Environmental Protection Agency, the Department of Energy, the American Institute for Cancer Research, the Science Foundation of Ireland, the Swiss Science Foundation, and the National Science Centre of Poland.  He was also a recipient of a MERIT Award from the National Institutes of Health.  Professor LaVoie presently serves as a member of the Internal Advisory Board for the Cancer Institute of New Jersey. Professor LaVoie’s current research interests include the development of novel cancer chemotherapeutic agents and antiviral agents for the prevention and treatment of influenza A infection.  In addition, his laboratory is working to develop new antibiotics capable of overcoming multidrug-resistant bacteria. Honorary Editorial Board of Drug Design, Development and Therapy (46) Members Editor-in-Chief Dr Pilch Drug Design, Development and Therapy Associate Editor Professor LaVoie Professor Adinoff Bryon Adinoff, Professor and Distinguished Professor in Alcohol and Drug Abuse Research, Chief, Division on Addictions, Department of Psychiatry, Univesity of Texas Southwestern Medical Center at Dallas, VA North Texas Health Care System, Dallas, TX, USA Professor Alavi Abass Alavi, Professor of Radiology and Neurology, Chief, Division of Nuclear Medicine, Director, Research Education, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA Dr Aldrich-Wright Janice Aldrich-Wright, School of Biomedical and Health Sciences, College of Health and Science, University of Western Sydney, Penrith, NSW, Australia Professor Ali-Osman Francis Ali-Osman, Margaret Harris and David Silverman Distinguished Professor of Neuro-Oncology Research, Department of Surgery, Duke University School of Medicine, Durham, NC, USA Professor Amiji Mansoor M. Amiji, Professor and Associate Department Chairman, Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA, USA Professor Anastasi Joyce K Anastasi, Helen F Pettit Professor of Clinical Nursing, School of Nursing, Columbia University, New York, NY, USA Professor Baguley Bruce Baguley, Professor and Co-Director, Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand Professor Baird Andrew Baird, Professor, La Jolla Institute for Molecular Medicine, San Diego, CA, USA Professor Bardo Michael T. Bardo, Professor of Psychology and Director, Center for Drug Abuse Research Translation (CDART) BBSRB, University of Kentucky, KY, USA Dr Bergey Earl J Bergey, Biophotonics, Institute for Lasers, Photonics and Biophotonics, State University of New York at Buffalo, Buffalo, NY, USA Professor Bilder Robert M Bilder, Professor of Psychiatry, Biobehavioral Sciences and Psychology, Chief of Medical Psychology-Neuropsychology, University of California at Los Angeles, Los Angeles, CA, USA Professor Bradford DiAnne Bradford, Professor of Clinical Psychiatry, Director, Minority Mental Health Research Program, Morehouse School of Medicine, Atlanta, GA, USA Professor Chaires Jonathan B Chaires, James Graham Brown Endowed Chair in Biophysics, James Graham Brown Cancer Center, University of Louisville, KY, USA Professor Chancellor Michael Chancellor, Professor, Department of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA Professor Cook James M. Cook, University Distinguished Professor, Organic Chemistry, Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, USA Professor DePinho Ronald DePinho, Professor of Medicine (Genetics), Harvard Medical School, Director, Center for Applied Cancer Science, DFCI, Dana-Farber Cancer Institute, Boston, MA, USA Professor Diamond Michael P. Diamond, Kamran S. Moghissi and Associate Chair of Ob/gyn, Director of the Division of Reproductive Endocrinology and Infertility, Wayne State University, Detroit, MI, USA Professor Dubinett Steven M. Dubinett, Professor of Medicine and Pathology, Chief, Division of Pulmonary and Critical Care Medicine; Director, UCLA Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA Professor Egli Martin Egli, Professor, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA Professor Gerson Stan Gerson, Asa and Patricia Shiverick Professor of Hematological Oncology, Director, Case Comprehensive Cancer Center, Center for Stem Cell and Regenerative Medicine, Case Western Reserve University, Cleveland, OH, USA Professor Giles Francis J. Giles, Professor and Chief, Division of Hematology and Medical Oncology, University of TX Health Science Center, San Antonio, TX, USA Professor Hruby Victor J Hruby, Regents Professor of Chemistry, Department of Chemistry, University of Arizona, Tucson, AZ, USA Professor Kosten Thomas R. Kosten, Jay H. Waggoner Chair and Professor, Psychiatry and Neuroscience, Baylor and VA, Houston, TX, USA Professor Kranz David M. Kranz, Phillip A. Sharp Professor of Biochemistry, Department of Biochemistry, University of Illinois at Urbana-Champaign, IL, USA Dr Li Aiqun Li, PhD, Senior Scientist, Pharmacokinetics and analytical biotech CoMentis, Oklahoma City, OK, USA Professor Lubman David M. Lubman, Maude T. Lane Professor of Surgery, Professor of Pathology and Chemistry, University of Michigan, Ann Arbor, MI, USA Professor Moeller F. Gerard Moeller, Professor, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, USA Professor Ortiz de Montellano Paul Ortiz de Montellano, Professor of Chemistry, Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology, University of California at San Francisco, San Francisco, CA, USA Dr Piette John D. Piette, Professor of Internal Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA Professor Rossi John Rossi, Chairman and Professor, Division of Molecular Biology, Dean, Graduate School of Biological Sciences, City of Hope, Duarte, CA, USA Professor Rubin Eric E. Rubin, Professor, Medicine and Pharmacology, Robert Wood-Johnson Medical School, Director of Investigational Therapeutics, The Cancer Institute of New Jersey, NJ, USA Professor Sadee Wolfgang Sadée, S. and L. Felts Mercer Professor of Medicine and Pharmacology, Department of Pharmacology, College of Medicine, Ohio State University, Columbus, OH, USA Professor Shafer Richard Shafer, Professor of Pharmaceutical Chemistry, University of Califonia at San Francisco, San Francisco, CA, USA Professor Smith Charles D. Smith, Professor and Charles and Carol Cooper Chair in Pharmacy, Co-Endowed Chair, Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC, USA Dr Sofuoglu Mehmet Sofuoglu, Department of Psychiatry, Yale University, West Haven, CT, USA Professor Stiles Alan D. Stiles, Brewer Distinguished Professor and Chair, Department of Pediatrics, Physician-in-Chief, NC Children's Hospital, University of North Carolina, Chapel Hill, NC, USA Professor Tan Ming T. Tan, Head and Professor of Biostatistics, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA Professor Tan Weihong Tan, Professor and Associate Director, Department of Chemistry and Shands Cancer Center, University of Florida, Gainesville, FL, USA Professor Tew Kenneth D. Tew, Professor and Department Chairman, Cancer Drug Development, Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA Professor Tor Yitzhak Tor, Professor of Chemistry and Traylor Scholar in Organic Chemistry, Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA Professor Tricot Guido J. Tricot, Professor, University of Arkansas for Medical Sciences, Myeloma Institute for Reserch and Therapy, Little Rock, AK, USA Professor Trudell Mark L. Trudell, University Research Professor, Department of Chemistry, University of New Orleans, New Orleans, LA, USA Dr Unger Gretchen M. Unger, Chief Scientific Officer, GeneSegues, Inc, Chaska, MN, USA Professor Waldman Scott Waldman, Professor and Chair, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA Professor Waring Michael J. Waring, Professor of Chemotherapy, Department of Pharmacology, University of Cambridge, Cambridge, UK Professor Zhou Shufeng Zhou, Prof of Pharmacology & Molecular Medicine, Assoc Vice President of Global Medical Development, Assoc Dean of International Research, & Chair of the Depart of Pharmaceutical Sciences, Colleges of Pharmacy and Medicine, University of South Florida, Tampa, Florida, USA